Vepdegestrant for ESR1-mutated breast cancer
Trends in Pharmacological Sciences · 2026-08 · 47 (8) · 940-941
DOI: 10.1016/j.tips.2026.06.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Pharmacological Sciences, 2026-08. Verfasst von Ryan S MacLeod und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT 06510, USA; Section of Endocrinology, Diabetes and Metabolism, …. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NINDS NIH HHS, NIH.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT 06510, USA; Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Yale School of Medicine, New Haven, CT 06510,…
- Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: chuan-ju.liu@yale.edu.
Förderung
- NIAMS NIH HHS
- NINDS NIH HHS
- NIH
Zitieren
APA
MacLeod, R. S., & Liu, C. J. (2026). Vepdegestrant for ESR1-mutated breast cancer. Trends in Pharmacological Sciences, 47(8), 940-941. https://doi.org/10.1016/j.tips.2026.06.009
Vancouver
MacLeod RS, Liu CJ. Vepdegestrant for ESR1-mutated breast cancer. Trends in Pharmacological Sciences. 2026;47(8):940-941. doi:10.1016/j.tips.2026.06.009
BibTeX
@article{MacLeod2026,
author = {MacLeod, Ryan S and Liu, Chuan-Ju},
title = {Vepdegestrant for ESR1-mutated breast cancer},
journal = {Trends in Pharmacological Sciences},
year = {2026},
volume = {47},
number = {8},
pages = {940--941},
doi = {10.1016/j.tips.2026.06.009}
}
EUVIMED